Breaking News, Collaborations & Alliances

Emergent BioSolutions Inks $480M Deal with J&J

CDMO signs five-year agreement for large-scale drug substance manufacturing for J&J’s lead COVID-19 vaccine candidate.

By: Contract Pharma

Contract Pharma Staff

Emergent BioSolutions has entered a five-year manufacturing services agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximate...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters